World CNS Summit South Korea 2026 | CNS CRO for Biotechs
Meet Avance Clinical at World CNS Summit South Korea 2026.
Search results
We found 64 results for: “globalready”
Oncology CRO | Avance Clinical at ESMO Congress 2026
Avance Clinical's Oncology Center of Excellence meets sponsors at ESMO Congress 2026 (23–27 Oct, Madrid) to talk about trial strategy. Book a meeting.
Avance Clinical at BIO-Europe 2026 | Early-Phase CRO
Avance Clinical, Australia's early-phase CRO, exhibits at BIO-Europe 2026, Booth #8-24. FDA/EMA-accepted data and fast study start-up. Book a meeting.
AusBiotech International Conference 2026 | Early-Phase CRO for Biotechs
Avance Clinical is exhibiting at AusBiotech International Conference 2026 on the Gold Coast.
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026
Global CRO expands its operational footprint into Singapore and Malaysia, strengthens China presence, and grows India operations - creating a powerhouse in the Asia Pacific region.
Frost & Sullivan’s 2026 Global Company of the Year
Frost & Sullivan is pleased to announce that Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology contract research organization (CRO) industry for its outstanding achievements in innovation, strategy execution, and customer impact.
AACR Annual Meeting 2026
Meet Avance Clinical at the AACR Annual Meeting 2026 in San Diego.
Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S-Based LumaBridge
Avance Clinical today announced the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials.
Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge
Avance Clinical today announced the acquisition of LumaBridge, a specialized U.S.-based clinical CRO with deep expertise in oncology trials.
Avance Clinical Showcases Early Phase Expertise and the Australian Advantage for EU Biotechs at BIO-Europe Vienna
Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data